GlassScriptPhysician profile
Vani S Reddi
NPI 1407803299
$11,589.80
in general payments reported to CMS, 2019-2025
39 companies · $1,413 in 2025
The $1,413 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,129 · 2020: $969 · 2021: $1,890 · 2022: $1,768 · 2023: $1,035 · 2024: $1,386 · 2025: $1,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,801 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,801.14 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,983.95 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,702.40 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,289.78 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $1,229.57 | 2019-2025 | |
| Amgen INC. | $888.28 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $793.23 | 2021-2025 | |
| Lilly USA, LLC | $581.86 | 2019-2025 | Zepbound, Mounjaro, Kisunla |
| Merck Sharp & Dohme LLC | $402.77 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Takeda Pharmaceuticals U.S.A., INC. | $323.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $251.12 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $200.22 | 2021-2024 | |
| Exact Sciences Corporation | $193.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Radius Health, INC. | $183.87 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $177.75 | 2022 | |
| Amarin Pharma, INC. | $152.90 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vani Reddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.